Clinical Trials Sponsored by Dainippon Sumitomo Pharma Europe LTd.

Total 91 results

Dainippon Sumitomo Pharma Europe LTd.

Terminated

Assessment of Safety, Pharmacokinetics and Efficacy in a Combination Treatment With SMP-114

Rheumatoid Arthritis (RA)

Czech Republic, Germany, Poland, United Kingdom, Hungary, Netherlands
University of California, Irvine
Dainippon Sumitomo Pharma America

Completed

A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone

Schizophrenia

United States
Sumitomo Pharma Co., Ltd.

Terminated

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Schizophrenia

Japan, Taiwan, China, Philippines
Sumitomo Pharma Co., Ltd.

Completed

Long-term Study of DSP-5423P in Patients With Schizophrenia

Schizophrenia

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Schizophrenia

Japan, Korea, Republic of, Malaysia, Taiwan
Sumitomo Pharma Co., Ltd.

Completed

A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

Japan
Sumitomo Pharma Co., Ltd.

Completed

DSP-3025 A Phase 1 Study of Healthy Male Volunteers

Healthy

Japan
Sumitomo Pharma Co., Ltd.

Completed

DSP-3025 Study of Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season

Allergic Rhinitis | Healthy Volunteer

Japan
Sumitomo Pharma Co., Ltd.

Completed

Confirmatory Study of DSP-5423P in Patients With Schizophrenia

Schizophrenia

China, Japan, Korea, Republic of, Malaysia, Philippines, Russian Federation, Taiwan, Ukraine
Sumitomo Pharma Co., Ltd.

Terminated

A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

Schizophrenia

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease

Parkinson's Disease | Levodopa-induced Dyskinesia

Japan
Sumitomo Pharma Co., Ltd.

Completed

Study of DSP-7888 in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

Non-Small Cell Lung Cancer | Malignant Pleural Mesothelioma

Japan
Sumitomo Pharma Co., Ltd.

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

Schizophrenia

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Japan
Sumitomo Pharma Co., Ltd.

Completed

Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Schizophrenia

Japan, Korea, Republic of, Taiwan
Sumitomo Pharma Co., Ltd.

Completed

A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Advanced Solid Tumors

Japan
Sumitomo Pharma Co., Ltd.

Completed

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Schizophrenia

Japan, Korea, Republic of, Malaysia, Taiwan
Sumitomo Pharma Co., Ltd.

Completed

Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer

Lung Cancer

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas

Glioblastoma | Diffuse Intrinsic Pontine Glioma

Japan
Sumitomo Pharma Co., Ltd.

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia

Schizophrenia

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

Bipolar Depression

Lithuania, Malaysia, Russian Federation, Slovakia, Ukraine, Japan, Philippines, Taiwan
Sumitomo Pharma Co., Ltd.

Terminated

Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

Small-cell Lung Cancer

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

Bipolar I Disorder

Japan, Lithuania, Malaysia, Philippines, Russian Federation, Slovakia, Taiwan, Ukraine
Sumitomo Pharma Co., Ltd.

Completed

Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy

Diabetic Neuropathy

Canada
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone

Schizophrenia

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer

Lung Cancer

China
Sunovion
PPD; ICON Clinical Research; Covance; Dainippon Sumitomo Pharma America; ClinPhone...

Completed

SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)

Overactive Bladder Syndrome (OABS)

France, United Kingdom, United States, Estonia, Germany, Latvia, Lithuania, Poland, Spain
Sumitomo Pharma (Suzhou) Co., Ltd.

Terminated

The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

Schizophrenia

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

Schizophrenia

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

A Clinical Trial of Lurasidone in Treatment of Schizophrenia

Schizophrenia

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients (AHOCEP)

Chronic Kidney Disease

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Terminated

Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients

First Episode Schizophrenia | Social Function | Cognition Function | Blonanserin

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia

Schizophrenia

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder (TACGAD)

Generalized Anxiety Disorder

China
Sunovion
Sumitomo Pharma Co., Ltd.

Completed

Clinical Study of WT2725 in Patients With Advanced Malignancies

Cancer

United States
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate (ESAHOM)

Essential Hypertension

China
Sumitomo Pharma (Suzhou) Co., Ltd.
Sunovion

Terminated

A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression

Bipolar I Depression

China
Otsuka Pharmaceutical Development & Commercialization...
Sumitomo Pharma Co., Ltd.; Sumitomo Pharma America, Inc.

Recruiting

A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Chugai Pharma Europe Ltd.

Completed

Study of CH5132799 Administered Orally in Patients With Advanced Solid Tumors

Solid Tumors

United Kingdom
Mochida Pharmaceutical Company, Ltd.
Sumitomo Pharma (Suzhou) Co., Ltd.

Active, not recruiting

Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia

Hypertriglyceridemia

China
Astellas Pharma Europe Ltd.

Completed

Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients (CHORUS)

Kidney Transplantation

Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Poland, Portugal, Romania, Serbia, Spain, Taiwan, Thailand, United Kingdom, Vietna...
Astellas Pharma Europe Ltd.

Completed

Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis

Chronic Kidney Disease (CKD)

Sweden
Astellas Pharma Europe Ltd.

Completed

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice (BELIEVE)

Urologic Diseases | Overactive Bladder | Urinary Bladder Diseases | Urgency Incontinence | Urinary Bladder Overactive

Czechia, Denmark, Greece, Ireland, Slovakia, Spain, Sweden, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment (ELEVATE)

Non-diabetic Painful Peripheral Polyneuropathy | Postherpetic Neuralgia (PHN) | Peripheral Nerve Injury (PNI)

Armenia, Austria, Belarus, Belgium, Bulgaria, Czechia, Finland, France, Germany, Greece, Hungary, Italy, Poland, Portugal, Romania, Russian Federation, Slovakia, Slovenia, Spain, Sweden, Turkey, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. (BEYOND)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases

Greece, Ireland, Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovaki... and more
Astellas Pharma Europe Ltd.

Terminated

To Validate an Analytical Method to Measure Concentration of Tacrolimus in Blood Taken From Finger Pricks

Validation | Dried Blood Spot | Transplant Patients

France, United Kingdom
Astellas Pharma Europe Ltd.

Completed

Observation of the Use of QUTENZA™ in Standard Clinical Practice (ASCEND)

Peripheral Neuropathic Pain

Austria, Greece, Italy, Portugal, Spain, Switzerland, United Kingdom
Astellas Pharma Europe Ltd.

Completed

Vesitirim™ in Men Postmarketing Observational Study (VIM)

Overactive Bladder (OAB) | Lower Urinary Tract Symptoms (LUTS)

Ireland

Clinical Trials Sponsored by Dainippon Sumitomo Pharma Europe LTd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations